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VERY HIGH RISK OF THERAPEUTIC FAILURE WITH CHLOROQUINE FOR
UNCOMPLICATED PLASMODIUM FALCIPARUM AND P. VIVAX MALARIA IN
INDONESIAN PAPUA
IWA W. SUMAWINATA, BERNADETA, BUDHI LEKSANA, AWALLUDIN SUTAMIHARDJA, PURNOMO,
BUDI SUBIANTO, SEKARTUTI, DAVID J. FRYAUFF, AND J. KEVIN BAIRD
United States Naval Medical Research Unit No. 2, Jakarta, Indonesia; Provincial Health Service, Abepura, Papua, Indonesia;
Infectious Disease Research Center, Ministry of Health, Jakarta, Indonesia

Abstract. Chloroquine remains the first-line therapy for uncomplicated malaria in Indonesia. Among a series of trials
of chloroquine for malaria on this archipelago conducted since 1990, we now report the highest risk of therapeutic failure
yet observed. A clinical trial of standard chloroquine therapy for uncomplicated malaria at Arso PIR V in northeastern
Indonesian Papua was conducted during 1995. We enrolled 104 non-immune subjects infected with Plasmodium falciparum (n ⳱ 55), P. vivax (n ⳱ 29), or P. falciparum plus P. vivax (n ⳱ 20) and administered supervised standard
chloroquine therapy (10 + 10 + 5 mg/kg at 24-hour intervals). The 28-day cumulative incidence of therapeutic failure was
95% for P. falciparum, 84% for P. vivax, and 100% for mixed infections. Only one subject each for P. falciparum and
P. vivax remained free of parasites at day 28. All recurrent parasitemias occurred with whole blood levels of chloroquine
plus desethylchloroquine exceeding 100 ng/ml. These findings document almost complete failure of chloroquine against
P. falciparum or P. vivax near the northeastern coast of Indonesian Papua.
tribution mechanism, along with educating healthcare providers and patients. In the case of Indonesia, the fourth most
populous nation in the world, such commitments engage
many thousands of government officers and many millions of
citizens. In addition to compelling evidence of the inadequacy
of current antimalarials, changes to policy and practice will
require fiscal resources not currently available to the health
infrastructure.
This report contributes to the case for adopting alternative
therapies for uncomplicated P. falciparum and P. vivax malaria in Indonesian Papua by describing the highest risk of
therapeutic failure yet documented in the region. We know of
no other region in Indonesia with risk of therapeutic failure
even approaching that reported here from northeastern
Papua. Substantiation of this may allow singling out the region for the distribution and use of relatively expensive and
effective combined therapies. Thus limiting the scale of application would substantially diminish the hidden costs of
adopting new therapeutic strategies.

INTRODUCTION
Chloroquine still constitutes first-line therapy against uncomplicated malaria caused by Plasmodium falciparum and
P. vivax in many endemic areas. Combined therapeutic strategies under consideration by developing nations include chloroquine plus other standard antimalarials such as sulfadoxine/
pyrimethamine.1 Combining chloroquine with agents such as
chlorpheniramine, which apparently reverse the process responsible for resistance, constitute another approach. 2
Whether used as monotherapy or in combination with other
agents, chloroquine remains a mainstay for therapy of malaria
in the developing world. Thus, therapeutic assessment of
chloroquine constitutes a key element of strategic thinking in
the development of treatment policies.3,4
We have conducted assessments of chloroquine for treatment of uncomplicated P. falciparum and P. vivax in northeastern Papua (formerly known as Irian Jaya), Indonesia.5–8
Three of these reports described resistance to chloroquine in
P. vivax. Another study9 found relatively low risk of therapeutic failure with chloroquine therapy of P. vivax (22% at
day 14). Subsequent studies of P. vivax in the same region
found higher risk of therapeutic failure (31−53% at day 14).7,8
Similar studies in the region evaluated chloroquine combined
with primaquine7 or doxycycline10 against P. vivax. Risk of
therapeutic failure with chloroquine for P. falciparum at day
14 post-therapy ranged from 57% to 84% in this region.6,8,10
The continued use of chloroquine for uncomplicated
P. falciparum and P. vivax malaria in Indonesian Papua
points to the lack of practical therapeutic options in the setting of a frontier area of a developing nation. Indonesian
authorities have not adopted policies that would permit distribution of drugs such as mefloquine, either alone or as combined therapy, largely as a consequence of prohibitive cost.
Effective therapies may be purchased in bulk for as little as
US $1 per adult treatment (e.g., mefloquine plus artesunate as
marketed in Cambodia), but chloroquine or pyrimethamine/
sulfadoxine treatments cost approximately US $0.20 (as marketed in Indonesia). Moreover, the longer and more complex
dosing regimens of the new therapeutic agents carry the hidden and substantial cost of adapting the acquisition and dis-

MATERIALS AND METHODS
Study sites. The study was conducted during October and
November 1995 in Arso PIR V, in northeastern Papua, Indonesia. This transmigration village is located within 7 km of the
border with Papua New Guinea and approximately 50 km
south of the Pacific Ocean coast. The residents of Arso PIR V
were predominantly transmigrants from Java, consisting
mostly of young families. Most residents had moved into the
village by January 1995. Malaria in the region was hyperendemic to holoendemic and transmitted by mosquitoes of the
Anopheles punctulatus group.11 These mosquitoes feed predominantly in villages between dusk and dawn. All residents
shared approximately equal risk of exposure to biting
anophelines. Figure 1 shows the age-specific prevalence of
malaria at enrollment. Prevalence of parasitemia among the
349 of the approximately 1,100 residents sampled was 79%,
with a P. falciparum to P. vivax ratio of approximately 3:1.
Prevalence across age groups was not significantly different
(P > 0.2), and this corroborates cross-sectional studies elsewhere in the region,12 suggesting onset of acquired immunity
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FIGURE 1. Age-specific prevalence of malaria at enrollment in the
study. Pf ⳱ Plasmodium falciparum; Pv ⳱ P. vivax; yr ⳱ years.

in adults only after 12−24 months of exposure to infection.
We considered these findings objective evidence of a broad
lack of clinical immunity in the study population.
Study subjects. Study subjects were recruited from among
those found slide-positive during the cross-sectional screening. Subjects ranged in age from 5 to 40 years (median ⳱ 24).
Asexual parasitemia counts at enrollment ranged from 40 to
16,480/L for P. falciparum (geometric mean ⳱ 766/L) and
40−13,520/L for P. vivax (geometric mean ⳱ 824/L). We
excluded subjects meeting the criteria of the World Health
Organization for severe or complicated malaria, pregnant or
lactating women, and children less than five years of age.
Eligible subjects provided informed consent in accordance
with U.S. Navy regulations governing the use of human subjects of medical research (SECNAVINST 3900.39B). A protocol detailing this work was reviewed and approved by
American and Indonesian institutional review boards.
Therapy and follow-up. Subjects received directly observed
therapy with chloroquine phosphate (uncoated scored tablets
containing 150 mg base, Resochin™; P.T. Bayer Indonesia,
Jakarta, Indonesia) in daily doses of 10 mg/kg on day 0 and
day 1, and a 5 mg/kg dose on day 2. Subjects were observed
for 30 minutes and repeated doses vomited in that time. Primaquine therapy for subjects infected by P. vivax was withheld until day 28 or at time of rescue therapy (oral quinine
sulfate tablets; 10 mg/kg three times a day for seven days)
with recurrent parasitemia. Thick and thin blood films were
collected on days 0, 1, 2, 3, 4, 7, 11, 14, 18, 21, and 28, or at any
time a subject complained of illness. Blood films were collected at the home or place of work/school. Subjects were
queried about their recovery and well being during home
visits.
Microscopy. Thick and thin blood films were stained with
standard Giemsa reagents and examined under 1,000×,
oil immersion light microscopy by experienced and certified
research technicians. At least 200 fields were examined before a slide was considered negative. Positive blood films
were recorded by the count of asexual parasites per 200
white blood cells. This value was converted to parasites per
microliter of blood by assuming a white blood cell count of
8,000/L.

Whole blood chloroquine levels. Peripheral blood collected
into 100-l heparinized capillary tubes was expelled onto filter paper (No. 1; Whatman, Maidstone, United Kingdom)
discs on days 0 (before therapy), 3, and 28, or the day of
rescue therapy of recurrent parasitemia. These blots were
air-dried for several hours and placed into individual sealable
plastic envelopes. These were stored at ambient temperature
and protected from exposure to light or moisture for several
months prior to analysis. We extracted and measured by highperformance liquid chromatography levels of chloroquine
and its primary metabolite, desethylchloroquine (DCQ), using methods detailed elsewhere.8,13
Classification of the therapeutic response. We considered
recurrent parasitemia with P. falciparum during the 28-day
evaluation consistent with a resistant classification, provided
there was evidence of good absorption of therapy (day 3 level
of chloroquine plus DCQ > 500 ng/ml). For P. vivax, we
considered recurrent parasitemia during the 28-day evaluation resistant to chloroquine if it occurred with ⱖ 100 ng/ml of
chloroquine plus DCQ (the minimal effective concentration),
along with evidence of good absorption of therapy (> 500
ng/ml of chloroquine plus DCQ on day 3). The rationale for
P. vivax classification has been explained elsewhere.14 In this
non-immune population, we considered parasitemia objective
evidence of risk of clinical disease, whether disease was
present or not at the point of observation.
Risk of therapeutic failure. We used life tables to estimate
interval-specific and cumulative incidence (risk) of therapeutic failure. Cumulative incidence (CI) was calculated as follows: CIx ⳱ 1 − [(1 − CIx−1)(1 − IRx)], where IR is the
interval risk, X is the interval, and X - 1 is the prior interval.
Recurrences consistent with a resistance classification were
considered incident cases in the life table calculation.
Interpretation of the life table estimates of risk was according to species and interval of risk. For both P. falciparum and
P. vivax, the 14-day cumulative risk of therapeutic failure was
viewed as a conservative estimate of the prevalence of resistance to chloroquine in the community. These relatively early
recurrences were considered more likely to be recrudescence
than those appearing relatively late (days 15−28) when reinfection or relapse was more likely to confound the estimate of
risk. The 28-day cumulative risk of recurrence was viewed as
an estimate of therapeutic failure due to resistance, reinfection, or relapse.
RESULTS
Chloroquine plus DCQ blood levels. Table 1 lists the chloroquine plus DCQ whole blood levels prior to therapy on day
0, on day 3, or the day of recurrent parasitemia for P. falciparum or P. vivax. The mean level of chloroquine plus DCQ
prior to administration of supervised therapy was 198, 200,
and 234 ng/ml for P. falciparum, P. vivax, and mixed infections, respectively. The proportion of subjects with evidence
of chloroquine on day 0 was 92% for P. falciparum, 83% for
P. vivax, and 90% for mixed infections. The chloroquine plus
DCQ levels at day 3 confirmed uniformly good absorption,
with all subjects having > 500 ng/ml. The chloroquine plus
DCQ levels on the day of persistent or recurrent parasitemia
prompting alternative therapy were at least 142 ng/ml and as
high as 4,423 ng/ml. The proportion of subjects with persistent
or recurrent parasitemia with chloroquine plus DCQ levels
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TABLE 1
Mean (range) whole blood levels of chloroquine plus desethylchloroquine during evaluation
Day 0

Day 3

Day of recurrence

Infection

n

ng/ml (range)

n

ng/ml (range)

n

ng/ml (range)

% > MEC*

P. falciparum
P. vivax
P. falciparum plus P. vivax

51
29
20

198 (0–922)
200 (0–843)
234 (0–795)

51
29
20

2,069 (866–8,870)
1,704 (914–3,489)
1,588 (997–2,368)

49
25
18

714 (142–3,583)
889 (180–2,754)
953 (238–4,423)

98
100
100

* MEC ⳱ minimal effective concentration: 200 ng/ml for Plasmodium falciparum and 100 ng/ml for P. vivax.

exceeding the minimal effective concentration (200 ng/ml for
P. falciparum and 100 ng/ml for P. vivax) was 98% for P.
falciparum, 100% for P. vivax, and 100% for mixed infections.
Risk of therapeutic failure. Table 2A lists the life table calculation for estimating risk of therapeutic failure of chloroquine against P. falciparum. The evaluation began on day 0
with 55 subjects at risk. Almost half the subjects failed to clear
parasitemia by day 4 and thus prompted rescue therapy with
quinine. By day 14 of the evaluation, only 14 subjects remained at risk, and by day 28, only one subject remained free
of parasitemia. One subject was lost to follow-up and three
others required alternative therapy as a consequence of intercurrent parasitemia by P. vivax. The 14-day risk of therapeutic failure was 84%. At day 28, the risk was 95%.
Table 2B lists the life table calculation for estimating risk of
therapeutic failure of chloroquine against P. vivax. The evaluation began on day 0 with 29 subjects at risk. Seven subjects
failed to clear parasitemia by day 4 and thus prompted rescue
therapy with quinine. Three subjects had intercurrent P. falciparum parasitemia and received rescue therapy with quinine by day 4. By day 14, only nine subjects remained at risk,
and by day 28, only one subject remained free of parasitemia.
All losses to follow-up listed in the withdrawals column were
due to intercurrent P. falciparum prompting rescue therapy.
Evaluation of therapeutic failure for P. falciparum and P.
vivax mixed infections began on day 0 with 20 subjects at risk.
Thirteen of these failed to clear parasitemia by day 4 (10 P.

TABLE 2
Life table estimates of risk of therapeutic failure of chloroquine
A Plasmodium falciparum
Interval
(day)

Sample
at risk

Incident
cases

Withdrawals

Interval
risk

Cumulative
risk

0
4
7
11
14
18
21
28

55
54
29
24
14
8
2
1

0
25
5
10
5
5
0
0

0
0
0
0
1
1
1
1

0
0.4630
0.1724
0.4167
0.3707
0.6667
0
0

0
0.4630
0.5556
0.7408
0.8368
0.9456
0.9456
0.9456

Interval
(day)

Sample
at risk

Incident
cases

Withdrawals

Interval
risk

Cumulative
risk

0
4
7
11
14
18
21
28

29
29
29
19
9
8
1
1

0
0
3
3
0
3
0
0

0
0.2545
0.1714
0.2400
0.1111
0.6154
0
0

0
0.2545
0.3827
0.5309
0.5830
0.8396
0.8396
0.8396

falciparum and 3 P. vivax). By day 14, all of the remaining
seven subjects had recurrent parasitemia (6 P. falciparum and
1 P. vivax).
Table 3 lists the proportion of infections in this study population having parasitologic evidence and chloroquine plus
DCQ levels supporting the diagnosis of resistance to chloroquine. The total number of infections by P. falciparum or
P. vivax (placing the mixed infections in both columns) was 75
and 49. All withdrawals except one were due to the administration of alternative therapy for parasitemia by the other
species: 7 for P. falciparum and 25 for P. vivax. Plasmodium
falciparum interfered with the P. vivax evaluation in approximately half of the infections. Among the 67 P. falciparum
infections (all had adequate absorption), all but one required
alternative therapy, and all but another one occurred with
chloroquine plus DCQ levels above the minimal effective
concentration. Therefore, 99% of the P. falciparum infections
successfully evaluated ended with therapeutic failure. Among
the 24 infections by P. vivax that were evaluated (all had
adequate absorption), 23 ended with a requirement for alternative therapy. Therefore, 96% of infections by P. vivax fully
evaluated ended with a requirement for alternative therapy.
In almost all instances of early therapeutic failure, the subjects had substantially lower parasite counts and had recovered clinically. Later recurrences also had substantially lower
parasite counts relative to enrollment and most remained
asymptomatic. No enrolled subject progressed to severe or
complicated disease, and none required hospitalization during the evaluation.
DISCUSSION
These findings demonstrate very high risk of therapeutic
failure with standard chloroquine therapy for uncomplicated
P. falciparum and P. vivax malaria in northeastern Indonesian
Papua. The proportion of subjects successfully completing the
in vivo test and presenting evidence of resistance was 99%
and 96% for P. falciparum and P. vivax, respectively (Table
TABLE 3
Confirmed resistance to chloroquine at Arso PIR V, Papua

B Plasmodium vivax

0
7
5
3
1
4
0
0

Sample at risk
Withdrawals
Adequate absorption*
Recurrence with >MEC†
Resistant to chloroquine
% resistant to chloroquine

Plasmodium
falciparum

Plasmodium
vivax

75
8
67
66
66
99

49
25
24
23
23
96

* Adequate absorption was >500 ng/ml of chloroquine plus desethylchloroquine on day 3.
† MEC ⳱ minimal effective concentration: 200 ng/ml for P. falciparum and 100 ng/ml for
P. vivax.
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3). The estimates of 28-day cumulative incidence of therapeutic failure (Table 2) for these species were lower (95% and
84%) due to withdrawals caused by intercurrent parasitemia
by the other species, prompting therapy. By either method
of estimating risk for both species, chloroquine therapy routinely failed within 28 days. Comparing these estimates of
risk with earlier studies in the same region,5–9 suggests an
apparently rapid deterioration of therapeutic efficacy for
P. vivax.
An attractive option for bringing combined therapies to
bear on the problem of drug-resistant malaria is chloroquine
plus pyrimethamine/sulfadoxine. The interest in this regimen,
with good efficacy demonstrated in a few studies and interventions,15,16 stems largely from the relative ease with which
it could be adopted. Both drugs are already stocked by government-operated clinics across Indonesia. Health care providers need only change how they administer the drugs,
thereby substantially saving on administrative/education costs
compared with introducing new therapies. A critical question
for this strategy is efficacy against a backdrop of resistance to
chloroquine and pyrimethamine/sulfadoxine as monotherapies. When is it too late to apply the combined therapy with
a reasonable expectation of good efficacy? Finding that
threshold becomes a vital public health issue where deployment of combined chloroquine and sulfadoxine/pyrimethamine may be considered. Areas having risk of therapeutic
failure exceeding that threshold may be targeted for more
effective (and expensive) therapies. Reliable estimates of resistance to chloroquine and sulfadoxine/pyrimethamine
should guide information-based decisions on adopting either
a new first line combined therapy, or deploying relatively
expensive alternatives. In the specific case of northeastern
Papua, the available data6,8,10 support abandoning chloroquine therapy either as monotherapy or combined with another agent. This heavily malarious region seems a good candidate for targeted distribution of artemisinin derivatives
combined with mefloquine or another agent that has not yet
lost clinical efficacy.
Standard protocols for therapeutic assessments of drugs for
the treatment of uncomplicated malaria strive to accomplish
uniformity across laboratories and investigators representing
a wide range of capabilities. The tests present realistic goals
with respect to obtaining useful information in the setting of
a rural health clinic in the tropics. A national program successfully developing such a surveillance network will possess
a powerful tool for information-based decisions on malaria
therapy policies and practice. Indonesia has not yet developed such a network. The relatively few studies of the therapeutic response to standard antimalarials come from research
laboratories. Research laboratories may have compelling reasons to not follow standardized protocols for surveillance of
resistance. These facilities typically send a team of specialists
to a remote area with the intent of obtaining as much useful
information as possible within a practical time. For example,
teams of specialists living in Jakarta cannot remain indefinitely at a remote health clinic in far off Papua. Personal and
economic priorities necessarily minimize time spent in the
field. Therefore, it is not often possible to follow standardized
protocols designed and intended for rural health clinic staff
resident at the site. The passive collection of study subjects is
not practical for the visiting research team. Instead, research
teams actively seek out study subjects by mass slide screening,

essentially as described in this study. Also, we have found it
impractical to exclude patients with parasitemias less than
1,000/L for P. falciparum or less than 300/L for P. vivax. In
the areas we work, 85% of otherwise eligible subjects fall
below these levels. Strict adherence to this criterion would
result in a diminishingly small sample size within the time
constraints imposed by a visiting research team. Moreover,
systematic exclusion of relatively low-grade parasitemia, often representing the majority of patients presenting for treatment, could create a deeply biased sample with respect to
estimating risk of therapeutic failure in a community. We also
include patients with mixed infections of P. falciparum and
P. vivax. Our microscopists consistently and reliably detect
mixed infections and are not confused by the species identity
of the recurrence. The intent of broader inclusion criteria is
maximizing the collection of useful information obtained
from the remote post with a fixed and relatively brief period,
while also minimizing risk of sample bias in the estimate of
risk.
In summary, we documented nearly complete resistance
to chloroquine by P. falciparum and P. vivax in non-immune
Javanese migrants taking residence in hyperendemic to holoendemic northeastern Papua, Indonesia. We know of no
other area of Indonesia with such high risk of therapeutic
failure with chloroquine. These findings support adopting
a therapeutic strategy tailored to this region, and provide a
backdrop of risk of therapeutic failure for evaluations of
combined therapies that include chloroquine as treatment
options.
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